Goldstick, Lawrence
for the TRAILBLAZER-ALZ 2 Investigators
3 papers on CoChat
Most cited papers
- Verified · note
Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial
Sims, J. R., Zimmer, J. A., Evans, C. D., Lu, M., Ardayfio, P., Sparks, J., Wessels, A. M., Shcherbinin, S., Wang, H., Monkul Nery, E. S., et al. (2023) · JAMA
Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research
Cited by 2,932
- Verified
Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study
Kappos, L., Bar-Or, A., Cree, B. A. C., Fox, R. J., Giovannoni, G., Gold, R., Vermersch, P., Arnold, D. L., Arnould, S., Scherz, T., et al. (2018) · The Lancet
Multiple Sclerosis Research StudiesSphingolipid Metabolism and Signaling
Cited by 942
- Verified
Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: A phase 2b, randomised, double-blind, placebo-controlled trial
Reich, D. S., Arnold, D. L., Vermersch, P., Bar-Or, A., Fox, R. J., Matta, A., Turner, T., Wallström, E., Zhang, X., Mareš, M., et al. (2021) · The Lancet Neurology
Multiple Sclerosis Research StudiesChronic Lymphocytic Leukemia Research
Cited by 204
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free